BLOG

Gc-MAF and/or oral Colostrum MAF macrophage activation therapy is indicated in the treatment of any diseases where there is immune disfunction or where the immune system is compromised, such as: Cancer Autoimmune diseases Respiratory tract infections Autism Spectrum Disorders (ASD) Herpes Simplex virus (HSV) Epstein-Barr Virus (EBV) Chronic Fatigue Syndrome (CFS) Multiple sclerosis (MS) Cystitis Myalgic Encephalomyelitis (ME) Rheumatoid arthritis (RA) Urinary tract infection (UTI) Tuberculosis Lyme disease (Lyme borreliosis) Endometriosis Lupus (Systemic lupus erythematosus, SLE) Mycobacteria infections Parkinson’s disease Pneumonia infection Fibromyalgia Norovirus Malaria Warts caused by viral infection Herpes simplex virus (HSV) Q fever (Coxiella burnetii) Influenza virus (flu)...

Autism Spectrum Disorders (ASD) Autism Spectrum Disorders (ASD) are neurodevelopmental diseases characterized by impaired social interaction, repetitive behaviors, and deficient language and social skills. Reports of autism cases per 1,000 children grew dramatically in the US from 1996 to 2007. The rapid increase in the number of autism cases in such a short period of time suggests that environmental factors are responsible for or a significant contributing factor in these types of diseases. However, complexity arises due to interactions among multiple genes, the environment and epigenetic factors which do not change DNA but are heritable and influence gene expression. Chart...

Very important fact about GcMAF treatment. There are different generations in GcMAF therapy.  The first generation GcMAF was developed over 20 years ago.  Due to limited testing and clinical uses, the efficacy is unknown. We have developed the 2nd and 3rd Generation GcMAF with a new patented production process.  Therefore, our GcMAF is very unique.  Please note that our 2nd Generation GcMAF should not be colourless liquid, as it is produced from serum. Our 3rd Generation GcMAF products are classified as a food product in Japan, and they are available in forms of Capsules, Sprays and Lollies. Our 3rd Generation GcMAF products are not produced from...

In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment.   In June 2020 we applied to the COVID-19 Scientific Technical Triage of the US FDA for the evaluation of the rationale to study the efficacy of MAF Capsules in COVID-19 treatment. The US FDA in PreIND 151946 meeting response recommended a small proof of concept (POC) study as the initial step prior to the large-scale trial be run. The US FDA indicated recommendations including the major study endpoints addressing the...